Skip to contentI
iBio, Inc.
I
IBIOiBio, Inc. Q1 2024 · 10-Q
Revenue$50.00K$50.00K— vs Q1 2023 Net Income-$5.75M-$5.75MN/M vs Q1 2023 EPS Diluted-$4.80-$4.80N/M vs Q1 2023 Operating Income-$5,103,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
iBio, Inc. · CIK 1420720 · Engraved from SEC EDGAR
Margins · derivedOperating margin-10206.0%
Net margin-11492.0%
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end